Table 2 Whole-blood bactericidal activity (WBA) results.

From: Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model

 

Celecoxib alone

TB drug alone

TB drug + Celecoxib

Mean differencea (95% CI)

P valueb

TB drugs (RIF + PZA groups combined)

n = 18

n = 18

n = 16

  

WBAmax (ΔlogCFU)

0.14 (0.10)

−1.25 (1.28)

−1.16 (1.24)

−0.07 (−0.17, 0.04)

0.20

WBAcum(0–8) (ΔlogCFU)

0.03 (0.01)

−0.10 (0.13)

−0.10 (0.12)

−0.01 (−0.02, 0.00)

0.16

RIF group

n = 9

n = 9

n = 7

  

WBAmax (ΔlogCFU)

0.17 (0.09)

−2.48 (0.24)

−2.51 (0.23)

−0.03 (−0.25, 0.18)

0.72

WBAcum(0–8) (ΔlogCFU)

0.03 (0.01)

−0.22 (0.02)

−0.22 (0.03)

0.00 (−0.02, 0.02)

0.96

PZA group

n = 9

n = 9

n = 9

  

WBAmax (ΔlogCFU)

0.12 (0.10)

−0.03 (0.23)

−0.12 (0.10)

−0.09 (−0.22, 0.04)

0.14

WBAcum(0–8) (ΔlogCFU)

0.02 (0.01)

0.01 (0.03)

0.00 (0.01)

−0.01 (−0.03, 0.00)

0.09

  1. Values are mean (SD), and mean difference with 95% CI.
  2. aMean difference for TB drug with and without celecoxib is derived from those with paired data for the TB drug i.e. n = 16 for combined groups, n = 7 for RIF group, n = 9 for PZA group.
  3. bWBA values were compared between TB drug alone and TB drug plus celecoxib using a paired-sample t-test.
  4. P values for WBAmax and WBAcum versus zero: 1.00 and 1.00 (Celecoxib alone); <0.0001 and <0.0001 (RIF alone); 0.37 and 0.92 (PZA alone).
  5. Abbreviations: RIF, rifampicin; PZA, pyrazinamide; CI, confidence interval.
Back to article page